DIOSYNTH BIOTECHNOLOGY ENTERS LONG-TERM COMMERCIAL SUPPLY AGREEMENT WITH DENDREON CORPORATION

Diosynth Biotechnology has entered into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for prostate cancer. The product will be manufactured for market launch and commercial sale in the Diosynth Biotechnology state-of-the-art facility in North Carolina, US. Subsequent manufacturing may also be done at the large-scale cell culture facilities of Diosynth in the Netherlands.

Carolina Newswire (http://carolinanewswire.com/news/News.cgi?database=topstories.db&command=viewone&id=4003&op=t)